Sanofi Announces Soliqua™ 100/33 Now Available in the U.S. Jan 4, 2017 08:00AM
Sanofi Receives FDA Approval of Soliqua™ 100/33 for the Treatment of Adults with Type 2 Diabetes Nov 21, 2016 07:19PM
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes Jul 27, 2016 08:12PM
Sanofi (SNY) Says Phase 3 LixiLan-O, LixiLan-L Trials Met Primary Endpoints Jun 13, 2016 06:16AM
Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Jun 12, 2016 03:54PM


Sep 29, 2015 08:00AM Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Sep 14, 2015 08:00AM Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study
Jul 29, 2015 07:00AM Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint
Jun 8, 2015 02:16PM Sanofi's Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk
Jun 6, 2015 10:00AM Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin
Mar 19, 2015 07:00AM Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)
Mar 19, 2015 02:11AM Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide)